Self-administration of augmentation therapy for alpha 1-antitrypsin deficiency.
作者信息
Vianello A, Lococo S, Corda L, Torrazza M, Zuccarini G, Baderna P, Cinetto F, Bargagli E, Confalonieri P, Sanduzzi Zamparelli S, Bertagna De Marchi L, Molena B, Lionello F, Caminati M, Guarnieri G
机构信息
Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Referral Centre for Alpha 1-Antitrypsin Deficiency, ASST Spedali Civili, Brescia, Italy.
出版信息
IJTLD Open. 2025 Jan 1;2(1):53-55. doi: 10.5588/ijtldopen.24.0566. eCollection 2025 Jan.
Abstract
摘要
相似文献
1
Self-administration of augmentation therapy for alpha 1-antitrypsin deficiency.α1-抗胰蛋白酶缺乏症增强疗法的自我给药。
IJTLD Open. 2025 Jan 1;2(1):53-55. doi: 10.5588/ijtldopen.24.0566. eCollection 2025 Jan.
2
A review of augmentation therapy for alpha-1 antitrypsin deficiency.α1-抗胰蛋白酶缺乏症的增强治疗综述。
Expert Opin Biol Ther. 2012 Jun;12(6):685-700. doi: 10.1517/14712598.2012.676638. Epub 2012 Apr 14.
3
Recurrence of emphysema post-lung transplantation in a patient with alpha 1 antitrypsin deficiency (AATD).α1抗胰蛋白酶缺乏症（AATD）患者肺移植后肺气肿复发
Respir Med Case Rep. 2020 Nov 26;31:101309. doi: 10.1016/j.rmcr.2020.101309. eCollection 2020.
4
Diagnosis and augmentation therapy for alpha-1 antitrypsin deficiency: current knowledge and future potential.α-1抗胰蛋白酶缺乏症的诊断与强化治疗：当前认知与未来潜力
Drugs Context. 2023 Jul 20;12. doi: 10.7573/dic.2023-3-1. eCollection 2023.
5
Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.α-1抗胰蛋白酶缺乏症所致肺部疾病的治疗：一项系统评价
Int J Chron Obstruct Pulmon Dis. 2017 May 2;12:1295-1308. doi: 10.2147/COPD.S130440. eCollection 2017.
6
Randomized, Placebo-Controlled Trials in Alpha-1 Antitrypsin Deficiency.α-1抗胰蛋白酶缺乏症的随机、安慰剂对照试验
Ann Am Thorac Soc. 2016 Aug;13 Suppl 4:S370-3. doi: 10.1513/AnnalsATS.201510-684KV.
7
Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic.抗胰蛋白酶缺乏症患者的 Alpha 1 抗胰蛋白酶治疗：来自注册研究的观点和 COVID-19 大流行期间自我管理的实际考虑。
Int J Chron Obstruct Pulmon Dis. 2021 Nov 1;16:2983-2996. doi: 10.2147/COPD.S325211. eCollection 2021.
8
Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency.补体成分 3 的激活与α-1 抗胰蛋白酶缺乏症中的气道疾病和肺肺气肿有关。
Thorax. 2020 Apr;75(4):321-330. doi: 10.1136/thoraxjnl-2019-214076. Epub 2020 Jan 20.
9
Nine controversial questions about augmentation therapy for alpha-1 antitrypsin deficiency: a viewpoint.九个关于α-1 抗胰蛋白酶缺乏症增强治疗的有争议问题：观点。
Eur Respir Rev. 2023 Dec 6;32(170). doi: 10.1183/16000617.0170-2023. Print 2023 Dec 31.
10
The Role of Neutrophils in Alpha-1 Antitrypsin Deficiency.中性粒细胞在α-1抗胰蛋白酶缺乏症中的作用
Ann Am Thorac Soc. 2016 Aug;13 Suppl 4:S297-304. doi: 10.1513/AnnalsATS.201509-634KV.
本文引用的文献
1
Recommendations for the Implementation of the Self-Administration of Alpha-1 Antitrypsin.推荐阿法-1 抗胰蛋白酶的自我管理。
Int J Chron Obstruct Pulmon Dis. 2023 Aug 4;18:1691-1700. doi: 10.2147/COPD.S410611. eCollection 2023.
2
Augmentation Therapy for Alpha-1 Antitrypsin Deficiency: Patient Experiences With Self-Infusion, Home Providers, and Clinics.α-1抗胰蛋白酶缺乏症的增强治疗：患者自我注射、家庭护理人员及诊所的经历
Chronic Obstr Pulm Dis. 2023 Oct 26;10(4):392-399. doi: 10.15326/jcopdf.2023.0430.
3
Opinions and Attitudes of Pulmonologists About Augmentation Therapy in Patients with Alpha-1 Antitrypsin Deficiency. A Survey of the EARCO Group.肺科医生对 α-1 抗胰蛋白酶缺乏症患者进行增强治疗的意见和态度。EARCO 集团的一项调查。
Int J Chron Obstruct Pulmon Dis. 2022 Jan 5;17:53-64. doi: 10.2147/COPD.S346051. eCollection 2022.
4
Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic.抗胰蛋白酶缺乏症患者的 Alpha 1 抗胰蛋白酶治疗：来自注册研究的观点和 COVID-19 大流行期间自我管理的实际考虑。
Int J Chron Obstruct Pulmon Dis. 2021 Nov 1;16:2983-2996. doi: 10.2147/COPD.S325211. eCollection 2021.
5
Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency.改善α-1 抗胰蛋白酶缺乏症患者的生活。
Int J Chron Obstruct Pulmon Dis. 2020 Dec 10;15:3313-3322. doi: 10.2147/COPD.S276773. eCollection 2020.
6
Diagnosis and management of α-antitrypsin deficiency in Europe: an expert survey.欧洲α-抗胰蛋白酶缺乏症的诊断与管理：一项专家调查。
ERJ Open Res. 2019 Mar 11;5(1). doi: 10.1183/23120541.00171-2018. eCollection 2019 Feb.
7
Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study.安全性、有效性及对遗传性血管性水肿患者生活质量影响的自我给药血浆源性纳米过滤 C1 抑制剂（Berinert®）：SABHA 研究。
Orphanet J Rare Dis. 2018 Apr 10;13(1):51. doi: 10.1186/s13023-018-0797-3.
8
Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.静脉增强治疗与严重 α1 抗胰蛋白酶缺乏症（RAPID）的肺密度：一项随机、双盲、安慰剂对照试验。
Lancet. 2015 Jul 25;386(9991):360-8. doi: 10.1016/S0140-6736(15)60860-1. Epub 2015 May 27.
9
Essential rules and requirements for global clinical trials in rare lung diseases: a sponsor's standpoint.罕见肺病全球临床试验的基本规则和要求：申办方视角
Respir Investig. 2015 Jan;53(1):2-6. doi: 10.1016/j.resinv.2014.09.001. Epub 2014 Nov 26.
10
Learning intravenous infusion in haemophilia: experience from the Netherlands.血友病患者静脉输液治疗培训：荷兰经验。
Haemophilia. 2012 Jul;18(4):516-20. doi: 10.1111/j.1365-2516.2012.02752.x. Epub 2012 Feb 1.
Zotero 插件